Form 8-K - Current report:
SEC Accession No. 0001213900-21-056759
Filing Date
2021-11-04
Accepted
2021-11-04 16:20:39
Documents
14
Period of Report
2021-11-04
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea149766-8k_nektarthera.htm   iXBRL 8-K 25814
2 PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS THIRD QUARTER 2021 FINANCIAL R ea149766ex99-1_nektarthera.htm EX-99.1 95636
6 GRAPHIC ex99-1_001.jpg GRAPHIC 2062
  Complete submission text file 0001213900-21-056759.txt   308671

Data Files

Seq Description Document Type Size
3 XBRL LABEL FILE nktr-20211104_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE nktr-20211104_pre.xml EX-101.PRE 22355
5 XBRL SCHEMA FILE nktr-20211104.xsd EX-101.SCH 3019
7 EXTRACTED XBRL INSTANCE DOCUMENT ea149766-8k_nektarthera_htm.xml XML 3491
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

EIN.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 211380314
SIC: 2834 Pharmaceutical Preparations